R(+)-N-formyl-propargyl-aminoindan

Patent metadata

Field	Value
Publication number	US-9346746-B2
Application number	US-201213647685-A
Country	US
Kind code	B2
Filing date	Oct 9, 2012
Priority date	Oct 10, 2011
Publication date	May 24, 2016
Grant date	May 24, 2016

Abstract

The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan.

First claim

What is claimed is:

1. An isolated compound having the structure:

2. A composition comprising a compound having the structure:

wherein the composition is free of rasagiline or a salt thereof.

3. A process for preparing R(+)-N-formyl-propargyl-aminoindan recited in claim 1 comprising the steps of:
a) mixing R-(+)-N-Propargyl-1-aminoindan with formic acid in a first solvent at a temperature of less than 30′C;
b) evaporating the first solvent to obtain an oil;
c) dissolving the oil in a second solvent to form a solution; and
d) isolating and obtaining R(+)-N-formyl-propargyl-aminoindan from the solution.

4. A pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, citric acid, R(+)-N-formyl-propargyl-aminoindan, and at least one pharmaceutically acceptable carrier,
wherein R(+)-N-formyl-propargyl-aminoindan is present in the pharmaceutical composition in an amount greater than about 0.04% by weight, relative to the amount of rasagiline, based on a determination by a HPLC method.

5. The pharmaceutical composition of claim 4 , wherein the amount of R(+)-N-formyl-propargyl-aminoindan is not more than about 0.5% by weight, relative to the amount of rasagiline, based on a determination by a HPLC method.

6. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is less than one week old, and the temperature during the less than one week did not exceed ambient temperature.

7. The pharmaceutical composition of claim 4 , which comprises rasagiline as free base.

8. The pharmaceutical composition of claim 4 , which comprises the pharmaceutically acceptable salt of rasagiline, and which salt is rasagiline citrate.

9. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is a solid pharmaceutical composition.

10. The pharmaceutical composition of claim 9 , which is in tablet form.

11. The pharmaceutical composition of claim 10 having a core and a coating, wherein the core of the tablet comprises an amount of rasagiline as free base, citric acid and mannitol.

12. The pharmaceutical composition of claim 11 wherein in the core of the tablet the weight ratio of mannitol to citric acid is between 45 to 1 and 10 to 1.

13. The pharmaceutical composition of claim 12 wherein in the core of the tablet the weight ratio of mannitol to citric acid is between 30 to 1 and 25 to 1.

14. The pharmaceutical composition of claim 12 having a core and a coating, wherein the core of the tablet comprises an amount of rasagiline and citric acid, about 59.9% of mannitol, about 0.53% of aerosil, about 6.6% of starch NF, about 26.3% of pregelatinized starch, about 2.0% of stearic acid, and about 2.0% of talc, by weight, relative to the weight of the core of the tablet.

15. The pharmaceutical composition of claim 14 , wherein the core of the tablet comprises an amount of rasagiline and citric acid, 45.5 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, and the coating of the tablet comprises two coating layers, of which the inner of the two coating layers comprises 3.5 mg of hypromellose and the outer of the two coating layers comprises 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine.

16. The pharmaceutical composition of claim 10 , wherein the amount of rasagiline in the core is 0.5 mg.

17. The pharmaceutical composition of claim 10 having a core and a coating, wherein the core of the tablet comprises an amount of rasagiline and citric acid, about 59.2% of mannitol, about 0.53% of aerosil, about 6.6% of starch NF, about 26.3% of pregelatinized starch, about 2.0% of stearic acid, and about 2.0% of talc, by weight, relative to the weight of the core of the tablet.

18. The pharmaceutical composition of claim 17 , wherein the core of the tablet comprises an amount of rasagiline and citric acid, 45.0 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, and the coating of the tablet comprises two coating layers, of which the inner of the two coating layers comprises 3.5 mg of hypromellose and the outer of the two coating layers comprises 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine.

19. The pharmaceutical composition of claim 10 , wherein the amount of rasagiline in the core is 1.0 mg.

20. The pharmaceutical composition of claim 10 , wherein not more than about 1.0% by weight of rasagiline citramide or a salt thereof is in the pharmaceutical composition relative to the amount of rasagiline, based on a determination by a HPLC method.

21. A process for preparing a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, comprising:
a) obtaining a batch of rasagiline or a pharmaceutically acceptable salt thereof;
b) analyzing the batch for the presence of the compound recited in claim 1 by a suitable apparatus; and
c) preparing the pharmaceutical composition from the batch only if the batch is determined to have less than about 0.5% of the compound by weight relative to the amount of rasagiline.

22. A process for preparing a packaged pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof comprising:
a) obtaining a pharmaceutical composition of rasagiline or a pharmaceutically acceptable salt thereof;
b) analyzing the pharmaceutical composition for the presence of the compound recited in claim 1 by a suitable apparatus; and
c) packaging the pharmaceutical composition only if the amount of the compound is not more than about 0.5% by weight relative to the amount of rasagiline.

23. A process of distributing a validated batch of a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, comprising
a) obtaining a batch of the pharmaceutical composition;
b) performing stability testing with a sample of the batch;
c) determining the total amount of the compound recited in claim 1 in the sample of the batch by a suitable apparatus after stability testing;
d) validating the batch for distribution only if the sample of the batch after stability testing is determined to have not more than about 1.0% by weight of the compound relative to the amount of rasagiline; and
e) distributing the validated batch.

24. A method for treating Parkinson's disease in a patient comprising administering to the patient an amount of the pharmaceutical composition of claim 4 effective to treat Parkinson's disease in the patient.

Assignees

• Teva Pharma

Inventors

• Safadi Muhammad
• Frenkel Anton
• Keisar Michal
• Licht Danit
• Bahar Eliezer
• Lidor-Hadas Ramy
• Zholkovsky Marina
• Cohen Rachel

Classifications

• A61P25/16

  Anti-Parkinson drugs · CPC title

• C07C233/03 Primary

  with carbon atoms of carboxamide groups bound to hydrogen atoms · CPC title

• A61K9/2866

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• C07B2200/07

  Optical isomers · CPC title

• C07C2602/08

  the other ring being five-membered, e.g. indane · CPC title